Amyris

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Earnings data Q1 2024

The principal business of Tara Gold Resources Corp. is the acquisition, exploration and development of high-quality precious metals projects with potential for economic commercial value. Tara Gold is currently focused on acquiring and developing properties in the natural resource belt of the Sierra Madre Occidental and other prolific areas in the states of Chihuahua, Sonora, and Sinaloa, Mexico.  Tara Gold provides investors growth exposure with a diversified exploration portfolio, multiple multi-million ounce targets and several near term production scenarios. Tara Gold owns equity positions in Cayden Resources Inc. (TSX-V: CYD) and Tara Minerals Corp. (TARM.OB), a public US company which explores and develops high-quality precious & non-precious metals and mineral projects in Mexico.

Amyris: Sub-Scale With High Fixed Costs And Limited Growth

Amyris, Inc. (NASDAQ: AMRS) is a small-cap company with a market cap of just over $381 million at the time of this writing. And the stock is a legitimate penny stock, with shares trading just over the $1 mark in early morning trading on April 17, 2023.

Amyris May be Oversold, but is it Worth Fighting the Shorts?

Amyris (AMRS) and Givaudan collaborate to leverage the former's technological platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients.

Amyris (AMRS) and Givaudan Close Cosmetic Ingredients Deal

Leveraging Amyris' industry-leading biotechnology platform in Beauty for the development and supply of clean sustainable ingredients EMERYVILLE, Calif. , April 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and CleanScreen™, the sustainable sun protector.

AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN

Record revenues in the Consumer segment drive Amyris' (AMRS) top line in the fourth quarter.

Amyris (AMRS) Q4 Earnings and Revenues Lag Estimates

Amyris, Inc. (NASDAQ:AMRS ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President and Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call Participants Colin Rusch - Oppenheimer Rachel Vatnsdal - JPMorgan Korinne Wolfmeyer - Piper Sandler Steven Mah - Cowen and Co. Sameer Joshi - H.C. Wainwright Laurence Alexander - Jefferies Operator Welcome to the Amyris Fourth Quarter 2022 Financial Results Conference Call.

Amyris, Inc. (AMRS) Q4 2022 Earnings Call Transcript

Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -160% and 27.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amyris, Inc. (AMRS) Reports Q4 Loss, Misses Revenue Estimates

Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior year Full year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%.

AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

Archer Aviation

BigBear.ai Holdings

Desktop Metal

Eos Energy Enterprises

Farfetch

Invitae

Penny stocks with unusual options activity today. The post 7 Penny Stocks To Watch Under $5 With Unusual Options Action appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Watch Under $5 With Unusual Options Action

EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets.

AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

AMTD International Inc

Asensus Surgical

LM Funding America

Mobilicom 

Sidus Space

Sorrento Therapeutics Inc

Will penny stock news put these on your buy or sell list this week? The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 To Watch Now After Big News

The bio-based sustainable blockbuster ingredients Squalane, Hemisqualane and Cleanscreen as well as development of future cosmetic ingredients from Amyris will accelerate both companies' leadership in biofermentation-based chemistry for the beauty industry. EMERYVILLE, Calif.

GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY

Ginkgo Bioworks Holdings

Twist Bioscience Corp

Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) all fell more than 75% from peak to trough, and may still have farther to fall.

The Next Big Disruptors? 3 Biotech Stocks Making Headlines.

Ally Financial

Black Hills

Shake Shack

T2 Biosystems

World Acceptance

In order for a free market to operate, investors must be willing to participate in both sides of the transaction, which brings us to the topic of the stocks to short this week. If you're feeling optimistic about the pessimistic trajectory of embattled enterprises, this list may be for you.

The 7 Best Stocks to Short This Week

EMERYVILLE, Calif. , Jan. 30, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced the launch of 4U by TiaTM , a new haircare line available exclusively at Walmart.

AMYRIS LAUNCHES 4U BY TIA™ HAIRCARE LINE EXCLUSIVELY AT WALMART

Faraday Future Intelligent Electric

MicroVision

Troika Media Group

Short Interest Stocks To Watch This Week Were you introduced to the

4 Penny Stocks To Watch This Week With High Short Interest

Uncertainty still surrounds the strategic transaction, but it is still likely to close in the coming weeks. Amyris' cash flow problems are improving rapidly, but a large amount of outside cash will likely still be needed to reach profitability.

Amyris: Darkest Before The Dawn

EMERYVILLE, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that management will present at the 41st Annual J.P.

AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE

EMERYVILLE, Calif. , Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that it has entered into a definitive purchase agreement for the purchase and sale of 20,000,000 shares of the Company's common stock and warrants to purchase up to an aggregate of 15,000,000 shares of common stock in a registered direct offering.

AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT

EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform today announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris' ingredients.

AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION

HTG Molecular Diagnostics

Landos Biopharma

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

Sangamo Therapeutics

thredUP

Penny stocks to buy according to analysts. Are they right?

3 Undervalued Penny Stocks According To Analysts

Givaudan SA

Amyris is on the cusp of closing a record strategic transaction slated to generate ~$500mm in cash value. All indications point to a transaction closing in the next two to three weeks.

Amyris: Show Us The Money

EMERYVILLE, Calif. , Nov. 30, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform today announced continued year-over-year growth on Cyber Monday, November 28, 2022.

AMYRIS CONSUMER BRANDS DELIVER 80% CYBER MONDAY LIKE-FOR-LIKE GROWTH

Agenus

Canopy Growth

Globalstar

Nordic American Tankers

Qurate Retail Inc

Transocean

SoFi Technologies

Viking Therapeutics

Penny stocks to watch with unusual options activity this week. The post 10 Top Penny Stocks With Unusual Options Activity, Time To Buy?

News for Amyris Stock (AMRS)